分析恩替卡韦联合肝爽颗粒对失代偿期乙型肝炎肝硬化临床治疗价值
摘要
关键词
全文:
PDF参考
[1]何平,郭春平,彭宁.恩替卡韦联合肝爽颗粒治疗乙型肝炎肝硬化失代偿期的效果[J].临床合理用药杂志,2021,14(36):
3.
[2]尹春丽.生物信息红外肝病治疗仪联合恩替卡韦治疗乙型肝炎肝硬化失代偿期的临床研究[J].现代医学与健康研究(电子
版),2022(018):006.
[3]Zhu Z,Liu Y,Wu W,et al.Liver Transplantation Reverses Hepatic Myelopathy in Hepatitis B-Related Decompensated Liver
Cirrhosis:Case Report and Review of the Literature[J].Transplantation Proceedings,2022,54(1):158-160.
[4]刘立,李俊义,刘春云,等.肝爽颗粒联合恩替卡韦对乙型肝炎肝硬化患者血浆D-二聚体的影响[J].实用医学杂志,2022
(010):038.
[5]刘鑫,黄健元,唐艳.分析恩替卡韦与前列地尔联合治疗乙型肝炎肝硬化腹水的临床价值[J].中文科技期刊数据库(全文版)
医药卫生,2021(4):2.
[6]Zhang M M,Zhang B F,Zhong K,et al.Effectiveness of Different Antiviral Treatments and Timing of the Treatment Initiation in
Hepatitis B Virus(HBV)-Infected Newborn Mice after Failure of Blocking Mother-to-Offspring Transmission[J]. 2023,37(1):
399-411.
[7]郑建军,段传梅,吴阳阳.前列地尔联合恩替卡韦治疗乙型肝炎肝硬化失代偿期患者的临床效果[J].河南医学研究,2022,
31(13):4.
[8]尹春丽.生物信息红外肝病治疗仪联合恩替卡韦治疗乙型肝炎肝硬化失代偿期的临床研究[J].现代医学与健康研究电子杂
志,2022(018):006.
[9]李奎国,汪艳侠,卜亚清,等.阿德福韦酯联合恩替卡韦治疗老年失代偿期乙型肝炎相关肝硬化疗效及对血清细胞因子的
影响[J].中国科技期刊数据库 医药,2022(6):4.
[10]郭俊贤.恩替卡韦抗病毒治疗乙型肝炎肝硬化失代偿期的效果,安全性及对患者肝功能的影响分析[J].黔南民族医专学报,
2021(004):034.
[11] Wang J,Yin S,Zhu L,et al.HBeAg Negativity is Associated with a Higher Risk of Liver-Related Death in Patients with Chronic
Hepatitis B Related Liver Cirrhosis[J].Diseases&Research,2022,2(1):1-8.
[12]何宇,李晶,王涛.恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎相关活动性肝硬化临床效果分析[J].系统医学,2021,6(14):3.
[13]Usama Riaz,Amna Tariq,Uzma Yasmeen,Hafiza Sobia Ramzan.Correlation between AST Platelet Ratio and Severity of Espohageal
Varices in Hepatitis B Induced Cirrhosis[J].Systematic Reviews in Pharmacy,2021,12(4):151-153.
[14] 张勇,刘丹,郑祥武.恩替卡韦胶囊联合肝爽颗粒在病毒性肝炎肝硬化治疗中的疗效观察[J].山西医药杂志,2023,52(4):5.
[15] Trebicka J,Fernandez J,Papp M,et al.PREDICT identifies precipitating events associated with the clinical course of acutely
decompensated cirrhosis - ScienceDirect[J].Journal of Hepatology,2021,74(5):1097-1108.
(40 摘要 Views, 45 PDF Downloads)
Refbacks
- 当前没有refback。